Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Capital Employed (2016 - 2026)

Akebia Therapeutics has reported Return on Capital Employed over the past 10 years, most recently at 11.33% for Q4 2025.

  • Quarterly Return on Capital Employed rose 4928.0% to 11.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11.33% through Dec 2025, up 4928.0% year-over-year, with the annual reading at 17.32% for FY2025, 5091.0% up from the prior year.
  • Return on Capital Employed was 11.33% for Q4 2025 at Akebia Therapeutics, up from 8.01% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 11.33% in Q4 2025 and troughed at 93.53% in Q1 2022.
  • The 5-year median for Return on Capital Employed is 32.64% (2023), against an average of 38.2%.
  • Year-over-year, Return on Capital Employed plummeted -3476bps in 2021 and then surged 7326bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 86.79% in 2021, then soared by 66bps to 29.85% in 2022, then fell by -12bps to 33.4% in 2023, then dropped by -14bps to 37.95% in 2024, then skyrocketed by 130bps to 11.33% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Return on Capital Employed are 11.33% (Q4 2025), 8.01% (Q3 2025), and 0.38% (Q2 2025).